Jul 6, 2023 | Press Release
Dr. Watson, the world’s leading investigator for the Lecanemab compound, letter and statement on the FDA approval of Lecanemab. We are all ecstatic here at ARTC with the approval of the Lecanemab. This is the first disease modifying treatment to be approved anywhere...
Nov 11, 2022 | Press Release
In September 2022, Eisai Co. and Biogen Inc. announced very positive topline results from the clinical trial of Lecanemab, an investigational treatment for mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s Disease. Eisai will be presenting the...
Sep 28, 2022 | Press Release
Dr. Watson at ARTC is the world’s leading investigator for the Lecanemab compound. On September 27, 2022 Eisai Co.,LTD and Biogen Inc. released the following statement. Read Press...
